Relative Cost of a Line of Vision in Age-Related Macular Degeneration

Ophthalmology

Volumn 114, Issue 5, 2007, Pages 847-854

  Smiddy, William E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; HEALTH CARE COST; HUMAN; LASER; LASER COAGULATION; LIFE EXPECTANCY; MEDICAL FEE; MEDICARE; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; SUBRETINAL NEOVASCULARIZATION; VISION; VITRECTOMY;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; PHARMACEUTICAL PREPARATIONS; VISION DISORDERS; VISUAL ACUITY;

EID: 34247358129     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.10.038     Document Type: Article

References (43)

1. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 100 (1982) 912-918
2. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 108 (1990) 816-824
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1113
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1220-1231
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
6. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
7. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
8. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
9. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
10. Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy: the third report from the Diabetic Retinopathy Study. Arch Ophthalmol 97 (1979) 654-655
11. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 103 (1985) 1644-1652
12. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial-Diabetic Retinopathy Vitrectomy Study report 3. Ophthalmology 95 (1988) 1307-1320
13. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
14. Burton T.C. Recovery of visual acuity after retinal detachment involving the macula. Trans Am Ophthalmol Soc 80 (1982) 475-497
15. Burton T.C. Preoperative factors influencing anatomic success rates following retinal detachment surgery. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 83 (1977) OP499-OP505
16. Smiddy W.E., Pimentel S., and Williams G.A. Macular hole surgery without using adjunctive additives. Ophthalmic Surg Lasers 28 (1997) 713-717
17. Mester V., and Kuhn F. Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129 (2000) 769-777
18. Brooks Jr. H.L. Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology 107 (2000) 1939-1948 discussion 1948-9
19. Wendel R.T., Patel A.C., Kelly N.E., et al. Vitreous surgery for macular holes. Ophthalmology 100 (1993) 1671-1676
20. Michels R.G. Vitrectomy for macular pucker. Ophthalmology 91 (1984) 1384-1388
21. Social Security Administration. Period life table (2002). http://www.ssa.gov/OACT/STATS/table4c6.html (updated June 27, 2006). Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed December 29, 2006.
22. Augustin A.J., and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 141 (2006) 638-645
23. Rubin G.S., Bressler N.M., and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation-TAP report no. 4. Retina 22 (2002) 536-544
24. Javitt J.C., Canner J.K., Frank R.G., et al. Detecting and treating retinopathy in patients with type I diabetes mellitus: a health policy model. Ophthalmology 97 (1990) 483-494 discussion 494-5
25. Smiddy W.E., Feuer W., Irvine W.D., et al. Vitrectomy for complications of proliferative diabetic retinopathy: functional outcomes. Ophthalmology 102 (1995) 1688-1695
26. Polk T.D., Smiddy W.E., and Flynn Jr. H.W. Bilateral visual function following macular surgery. Ophthalmology 103 (1996) 422-426
27. Assessing quality of life: beyond the Snellen chart. Eyenet (2004) 32-36 Jul/Aug
28. Scott I.U., Smiddy W.E., Schiffman J., et al. Quality of life of low-vision patients and the impact of low-vision services. Am J Ophthalmol 128 (1999) 54-62
29. William G.A. The economic realities of photodynamic therapy for treatment of AMD. Vitreoretinal surgery and techniques 13 2 (2004) 1 4-5.
30. Brown G.C., Sharma S., Brown M.M., and Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 118 (2000) 47-51
31. Brown G.C., Brown M.M., and Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 35 (2000) 127-133
32. Brown M.M., Brown G.C., Sharma S., et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 85 (2001) 327-331
33. Sharma S., Brown G.C., Brown M.M., et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 108 (2001) 2051-2059
34. Brown M.M., Brown G.C., Sharma S., et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 120 (2002) 481-484
35. Brown M.M., Brown G.C., Sharma S., and Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol 48 (2003) 204-223
36. Sharma S., Oliver-Fernandez A., Bakal J., et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 87 (2003) 259-261
37. Hopley C., Salkeld G., and Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 88 (2004) 982-987
38. Michels S., and Rosenfeld P.J. Treatment of neovascular age-related macular degeneration with ranibizumab/Lucentis. [in German]. Klin Monatsbl Augenheilkd 222 (2005) 480-484
39. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
40. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
41. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
42. Heier J.S., Antoszyk A.N., Pavan P.R., et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled multidose study. Ophthalmology 113 (2006) 633-642
43. Nataloni R. AMD treatment trends call attention to cost/benefit considerations. Retinal Physician (2006) 53-57 Jan